MDI Health

An Israeli company with headquarters in the US

MDI Health was founded in 2019 by Avishai Ben-Tovim, Dorit Dil Nahlieli and Yuval Kalev, according to CTech. The 2023 report describes research and development teams in Israel and in the United States. The company's current website says the team works remotely and the headquarters is in Los Angeles. In August 2025 Brad Margolis, who had previously been chief operating officer, was appointed CEO; in 2023 the role was held by Ben-Tovim. The leadership page presents Nahlieli as a founder and chief scientist. The company develops a medication management system for health insurers and care providers.

A review of all the drugs and the patient

The product carries out a personal analysis of drug treatment. According to the funding description, it looks at interactions between drugs together with the patient's medical history, lifestyle and other characteristics. Its goal is to help professionals with prescribing decisions and with a full review of the drugs taken together. The website stresses the combination of medical and pharmaceutical knowledge with artificial intelligence. The result is not just a general list of warnings, but recommendations tailored to the case. These are sent to professionals to use in the treatment process and in weighing risks and benefits.

How the analysis reaches the care team

The platform includes population management dashboards that help choose which cases to review first. After the analysis it shows recommendations ready to be passed on, and offers integration with the electronic health record or the population management system. According to the website, outreach to care providers can be tailored, and clinical and financial measures can be tracked. The company also describes identifying patients who may not keep taking their medication, and looking into the reasons. Fitting into the workflow is central to how the product is described: the system is aimed at review, prioritization and passing on recommendations, not only at answering a single question typed into the software.

The funding published in February 2023

On 14 February 2023 CTech reported a $20 million raise led by Intel Capital. Maverick Ventures Israel and existing investors, including Hanaco Ventures, Welltech Ventures and Arc Impact, took part in the round. According to the article, total funding at that point reached $26 million. The money was meant to expand the research and development teams in Israel and the United States and to meet demand.

Testing the recommendations against clinical pharmacists

On 25 September 2025 the company published a research collaboration with Stanford Medicine's applied artificial intelligence team. In the study design, the system and clinical pharmacists will separately analyze medical and insurance information of patients who take many drugs. A panel of senior pharmacists is to compare the recommendations and check their accuracy. The announcement said completion was expected in 2026. It describes an evaluation plan, not final results of the study. The product website also presents outcome tracking and tailoring of recommendations to reduce medications. The recommendations are passed to professionals as part of reviewing complex drug treatment.